GLP-1 receptor agonists, SGLT-2 inhibitors, and dual GIP/GLP-1 agonists target the molecular pathways behind diabetic retinopathy and may slow its progression, while AI-powered diagnostics now detect early eye disease with over 95% accuracy.
>95% detection accuracyAI-based algorithms for detecting non-proliferative diabetic retinopathy and predicting cardiovascular risk from retinal imaging
What the researchers found
Novel antidiabetic medications including GLP-1 receptor agonists, SGLT-2 inhibitors, and dual GIP/GLP-1 agonists target the key molecular pathways underlying early diabetic retinopathy: microvascular damage, inflammation, oxidative stress, and advanced glycation end products. These drugs may have the potential to reduce progression of non-proliferative diabetic retinopathy (NPDR), though clinical trial confirmation is expected.
The review also highlights that advanced diagnostic technologies — ultra-widefield fundus photography, OCT, OCTA, and AI-based algorithms — achieve over 95% accuracy in detecting NPDR and can predict systemic cardiovascular risk from retinal imaging.
Why it matters
Diabetic retinopathy affects a significant proportion of the world's 500+ million people with diabetes. Current eye treatments (laser, injections) address late-stage disease. If drugs patients are already taking for blood sugar control also protect their eyes at the molecular level, it could prevent millions of cases of vision loss without any additional treatment — a paradigm shift from reactive to preventive eye care in diabetes.
How the study worked
Narrative review of molecular mechanisms underlying diabetic retinopathy, the pharmacological profiles of novel antidiabetic drugs and their potential retinal effects, and advances in diagnostic imaging and AI-based detection algorithms.
What this study cannot tell us
This is a narrative review, not a systematic review or meta-analysis. Much of the evidence for retinal protective effects of GLP-1 agonists comes from preclinical studies and secondary analyses of cardiovascular outcome trials rather than dedicated retinopathy endpoint trials. The potential benefits are described as expected rather than proven. Early concerns about semaglutide and retinopathy progression in certain trials are not clearly addressed.
How to read the evidence
This is a narrative review that synthesizes preclinical evidence, secondary analyses, and emerging clinical data. The retinal protective effects of GLP-1 agonists are biologically plausible but not yet confirmed in dedicated retinopathy clinical trials.
When this study was published
Published in 2025, this is a very current review capturing the latest evidence on novel antidiabetic drugs and diabetic retinopathy, including dual GIP/GLP-1 agonists that have only recently entered clinical use.
The bigger picture
GLP-1-based therapies continue to demonstrate benefits far beyond blood sugar control — cardiovascular protection, kidney preservation, weight loss, and now potentially vision preservation. This review positions diabetic retinopathy as the next frontier for GLP-1 agonist benefits, while the convergence of AI diagnostics with targeted pharmacotherapy could transform how diabetic eye disease is managed at the population level.
Questions still open
- Will dedicated clinical trials confirm that GLP-1 agonists reduce diabetic retinopathy progression independently of their blood sugar-lowering effects?
- How do the retinal effects of dual GIP/GLP-1 agonists like tirzepatide compare to pure GLP-1 agonists?
- Can AI-based retinal screening be integrated with GLP-1 therapy decisions to identify which patients would benefit most from early treatment intensification?
Common questions
How might GLP-1 drugs protect the eyes in diabetes?
What role does AI play in detecting diabetic eye disease?
Read the original research
The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications.
Frontiers in medicine, 12, 1670643
Citation
Wen, Song; Xu, Chenglin; Yuan, Yue; Chen, Lijiao; Ren, Yishu; Xu, Zhimin; Jin, Jianlan; Li, Jiyu; Zhou, Ligang. (2025). The novel antidiabetic medications on diabetic retinopathy: relevant molecular mechanisms, advancing diagnostic innovations, and therapeutic implications.. Frontiers in medicine, 12, 1670643. https://doi.org/10.3389/fmed.2025.1670643